This combination therapy is commonly used to help with the temporary relief of symptoms associated with acute episodes like the common cold, flu, or seasonal allergies.

The primary symptomatic support is applied in addressing a frequent and disruptive cough, easing upper airway irritation, and helping with associated allergic symptoms such as runny nose and sneezing. This supportive relief is relevant in contexts involving heightened systemic burden where additional management of discomfort is needed. This supportive therapy assists with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods.

One key benefit of managing these acute symptoms contributes to the patient's improved comfort during periods of heightened symptoms. By significantly lessening the burden of cough and associated discomfort, this treatment supports general well-being during symptomatic phases.

Quick Fact: Relief for Disruptive Cough and Allergic Symptoms

Regulatory References

1. NIH DailyMed

Eligibility Scope

Allowed Population: The medication is officially indicated for use only in adults 18 years of age and older, reflecting a strict regulatory boundary for eligibility.

Populations for Whom Use is Contraindicated: Promethazine With Codeine is strictly prohibited for several populations due to the risk of life-threatening respiratory depression. This includes all children younger than 12 years of age and all pediatric patients under 18 years of age following tonsillectomy or adenoidectomy. Use is also formally contraindicated in individuals identified as ultra-rapid metabolizers of codeine and in patients with acute or severe bronchial asthma or lower respiratory tract symptoms.

Age and Condition-Based Restrictions:

• Adolescents (12–18 years): Use is generally avoided if risk factors for breathing problems are present, such as obstructive sleep apnea or severe pulmonary disease.
• Pregnancy and Lactation: Use is avoided during pregnancy due to the risk of Neonatal Opioid Withdrawal Syndrome. The medication is not recommended for use by breastfeeding women.
• Organ Function: Patients with severe hepatic or severe renal impairment should be managed with caution and require close monitoring, as specified in official prescribing information.
• Special Populations: The elderly, debilitated patients, and those with compromised respiratory function (e.g., COPD) require careful monitoring due to heightened risk.

The regulatory documentation for Promethazine With Codeine establishes specific restrictions and documented interaction patterns. The combination is formally contraindicated for co-administration with Monoamine Oxidase Inhibitors (MAOIs), necessitating a mandatory separation period of 14 days before starting therapy.

A major pharmacodynamic restriction applies to all other Central Nervous System (CNS) Depressants, including alcohol, benzodiazepines, and other opioids. Co-administration with these substances is documented to result in profound sedation and life-threatening respiratory depression.

The interaction profile is also shaped by pharmacokinetic patterns linked to Codeine's metabolism. Co-administration with CYP2D6 inhibitors (e.g., amiodarone, quinidine) is officially documented to increase codeine plasma concentrations while decreasing the level of the active metabolite, morphine. Similarly, CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) reduce codeine clearance, leading to increased exposure.

Other documented interactions include the enhancement of anticholinergic effects when co-administered with other anticholinergic agents. Population-specific interaction risks officially noted include ultra-rapid CYP2D6 metabolizers, who face an increased risk of toxicity, and patients with hepatic impairment, who may experience increased effects due to documented slower clearance.

Central Depression of the Cough Reflex Arc

The central depression of the cough center is initiated by the Codeine component, which acts as an agonist at mu-opioid receptors (mu-OR) primarily located in the brainstem's medullary cough center. This interaction hyperpolarizes the responsible neurons, thereby raising the neural threshold required to trigger the coughing reflex and directly reducing the central neuronal excitability.

Dual Antagonism of Histaminergic and Cholinergic Pathways

The second component, Promethazine, exerts its effects by acting as an antagonist at both Histamine H1 receptors and Muscarinic Acetylcholine receptors in the CNS and periphery. This dual blockade limits the excitatory effects of histamine on sensory nerves and diminishes glandular secretions by modulating the cholinergic autonomic pathway.

Additive Modulation of Central Nervous System Arousal

The pronounced CNS effects result from the additive mechanism of both ingredients. Codeine's mu-OR agonism contributes to general CNS depression, which is significantly amplified by Promethazine's widespread antagonism of H1 and muscarinic receptors in the brain's arousal centers, leading to substantial CNS depression.

The administration of Promethazine With Codeine is restricted to the oral route using the available liquid solution or syrup formulation. The general use principle is to limit treatment to the shortest duration necessary, consistent with the immediate need.

The standard dose for adults (age 18 and older) is 5 mL of the oral solution, which is intended to be administered every 4 to 6 hours as needed. The total intake is limited to a maximum of 30 mL within any 24-hour period. To ensure the integrity of the dosing regimen, a professional, milliliter-based measuring device must be used for administration, as common household spoons are not considered sufficiently accurate.

Dosing principles require careful attention for specific populations. For older adults, administration should generally be initiated at the lower end of the effective dosing range. A similar cautious approach is warranted for patients with known hepatic or renal impairment. The medication may be taken independently of meals. If the cough persists without adequate relief, the protocol mandates that the patient must be reevaluated by a prescriber in 5 days or sooner. For individuals utilizing the medication regularly over a prolonged period, the label indicates that a gradual dose tapering may be necessary when discontinuing treatment.

Research Evidence / Overview of Studies for Promethazine With Codeine

Evidence for Temporary Relief of Cough Associated with Common Cold

Research related to this medication was studied for temporary relief of symptoms associated with acute episodes. The evidence includes historical controlled clinical studies and extensive regulatory assessments that examine the physiological activity of both the anti-histamine and antitussive components. Studies monitored how symptoms evolved in the observed adult populations. Findings describe patterns observed in the studies, where short-term changes in measured cough frequency and severity scores were observed in the populations during periods of increased symptom activity. Data show patterns related to symptomatic changes were consistently observed over defined, short time intervals, consistent with the treatment duration explored for common cold symptoms.

A key research limitation is that data for the combination product often often relies on the established pharmacology of the individual ingredients and historical data. Comparative evidence is lacking for recent, large-scale randomized trials specifically designed to compare this combination against newer, non-opioid options. This means certainty remains low regarding the specific, symptomatic contribution of the combination compared to using either component alone.

Evidence for Temporary Relief of Cough and Symptoms Associated with Allergies

Studies conducted during periods of increased symptom activity have evaluated this medication for conditions characterized by fluctuating or episodic manifestations, such as seasonal allergies. The research explored short-term symptom changes, monitoring outcomes linked to inflammatory or irritative states, including sneezing, runny nose, and ocular symptoms. Reported findings indicate patterns related to changes in upper airway irritation and related symptoms. Furthermore, studies report that sedation was a consistently observed outcome.

Data show patterns related to short-term symptomatic changes, but comparative evidence is lacking, making it difficult to fully contextualize the findings. Research does not determine whether an individual will respond similarly to group patterns, and data for certain subgroups, such as those with varying allergy severity, remain insufficient.

Duration of Research and Long-term Follow-up

Evidence derived from settings with varying symptom burdens focuses exclusively on outcomes describing episodic or acute changes. The research exploring short-term symptom changes typically involves follow-up durations that were limited, consistent with the acute nature of the indications. Studies monitored responses over defined time intervals, usually covering hours to a few days (generally le 5 days).

There is limited information for long-term outcomes, and research does not characterize persistence of symptom change or any effects beyond the short-term treatment period. Long-term effects are not fully established, and no studies exist concerning the maintenance of stability over extended use.

Evidence in Specific Adult Populations

Research populations included in key clinical studies were adults (age ge 18 years) who were monitored during acute episodes. The results apply only to the populations studied, and specific data for subgroups defined by particular comorbid conditions are not often well-characterized in the main regulatory findings. Data for children under 12 years are insufficient; consequently, dedicated clinical research in these age groups is not available for the current label.

Research Gaps and Unanswered Questions

This concluding section synthesizes the main limitations cited by regulatory bodies and scientific literature. Data for the combination product is considered limited in several key areas. Comparative evidence is lacking to definitively contextualize the product's profile against newer standard care options. Research suggests that findings were mixed regarding the magnitude of cough suppression across various studies of the antitussive component. Consequently, evidence quality varies across studies, and data are still emerging in some research areas.

Key Studies & References Promethazine and Codeine Phosphate Syrup Official Labeling (Package Insert)

Common questions about Promethazine With Codeine (FAQ)

Q: What is the typical duration of the effects of Promethazine With Codeine?

A: Official product information indicates that the effects of Promethazine With Codeine generally last approximately four to six hours per dose. This duration aligns with the recommended dosing interval for the medication.

Q: What signs of a potentially serious problem, such as respiratory depression, should a user be aware of?

A: Regulatory documents emphasize that severe respiratory depression is a life-threatening risk. Signs of this serious problem that a user should be aware of include extreme sleepiness, confusion, or shallow and slow breathing.

Q: Is dry mouth a side effect that is associated with the promethazine ingredient?

A: Yes, official sources document dry mouth as a common side effect of this medication. This is linked to the promethazine component's effect of blocking certain nerve receptors, a property often referred to as being anticholinergic.

Q: What might happen if a patient who has developed a physical dependence stops the medicine suddenly?

A: Stopping the medicine abruptly in a person who has developed physical dependence can result in an opioid withdrawal syndrome. Official prescribing information indicates that a gradual dose tapering is often necessary to minimize this risk.

Q: What does it mean to be an 'ultra-rapid metabolizer' of codeine, and what is the risk involved?

A: An ultra-rapid metabolizer is a person whose body converts the codeine in the medicine into its active form, morphine, more quickly and completely than usual. This leads to higher morphine levels in the body, which significantly increases the risk of life-threatening respiratory depression (severe breathing problems) and overdose symptoms.

Q: What is the risk of developing uncontrolled body movements (dyskinesia) while using the medication?

A: The official label reports a risk of extrapyramidal symptoms associated with the promethazine component. These effects involve involuntary movements such as shakiness, stiffness, or jerking. The risk is noted as potentially higher in people who are dehydrated.

Q: Does Promethazine With Codeine interact with common anti-nausea medications?

A: Official warnings strictly caution against combining this drug with other Central Nervous System (CNS) depressants. If a common anti-nausea medication also causes sedation, co-administration may result in profound sedation and severe breathing risks.

Q: Are there specific warnings about combining this drug with muscle relaxants?

A: Regulatory documents include muscle relaxants as examples of Central Nervous System (CNS) depressants. Combining this medication with any CNS depressant can lead to dangerous outcomes, including profound sedation and severe, life-threatening respiratory depression.

Q: What is the risk of blood pressure dropping, especially when standing up, while taking this drug?

A: Hypotension (low blood pressure) is a documented adverse reaction. Official documents indicate that if a person experiences dizziness or faintness, a common suggestion is to lie down to help manage this effect.

Q: Can the promethazine component affect mental alertness more significantly than the codeine component?

A: Both active ingredients cause Central Nervous System (CNS) depression and contribute to sedation through an additive mechanism. The promethazine component is a strong antihistamine that is clinically recognized for its sedative effects and significantly amplifies the overall reduction in mental alertness.

Q: Does the medicine have anticholinergic effects, and what symptoms does this cause?

A: Yes, the promethazine component has documented anticholinergic effects, meaning it blocks certain receptors in the body. The resulting symptoms noted in official documents can include dry mouth and difficulty or problems urinating.

Q: How quickly does the cough-suppressing effect of the codeine component typically start to work?

A: Regulatory sources state that the antitussive (cough-depressing) action of the codeine component has been observed to start approximately 15 minutes after taking the oral dose. The peak effect is typically reached within 45 to 60 minutes.

Q: Are there common over-the-counter medications that interact with this medicine?

A: Official warnings cover specific pharmacological classes of drugs that interact, such as CNS depressants or certain enzyme inhibitors. Official guidance stresses the importance of reviewing all products with a healthcare provider before use, as some over-the-counter (OTC) medications fall into these categories.

Q: What is the official guidance regarding the sharing of Promethazine With Codeine with other people?

A: Official guidance states that this prescription medication should not be shared with any other person, even if they have the same condition. Because Promethazine With Codeine is a controlled substance, selling or giving it away is against the law and carries the potential to harm others.

Q: Is there a caution for people with a history of seizures when considering this product?

A: Yes, official warnings indicate that the promethazine component may lower the seizure threshold (increase the risk of seizures). Regulatory information notes that the medication is recommended for use with caution in patients with a history of seizures or a diagnosed seizure disorder, as it may worsen the condition.

Q: What are the general symptoms associated with Serotonin Syndrome when combined with other drugs?

A: Serotonin syndrome is a documented serious risk when this medication is combined with certain other drugs. General symptoms may include changes in mental status (such as agitation or hallucinations), autonomic instability (such as rapid heart rate or fluctuating blood pressure), and issues with muscle control (such as hyperreflexia or incoordination).

Q: How does the body eliminate the active ingredients in Promethazine With Codeine?

A: According to official product information, the active ingredients are primarily processed through metabolism in the liver by specific enzymes. Both the original drug and its inactive breakdown products are then mainly excreted from the body in the urine.

Q: Is there an increased risk of sunburn or sensitivity to light while taking this medicine?

A: Yes, photosensitivity (an increased sensitivity to light) is a documented side effect of this medication. Due to this risk, exposure to light, especially sunlight, may cause severe sunburns, blisters, and swelling.

Q: What is the clinical definition of Neuroleptic Malignant Syndrome (NMS) and its connection to promethazine?

A: Neuroleptic Malignant Syndrome (NMS) is a rare, potentially fatal condition reported with promethazine use. It is a symptom complex characterized by hyperpyrexia (very high fever), severe muscle rigidity, confusion or altered mental status, and evidence of autonomic instability (such as irregular pulse or blood pressure).

Q: Can taking this medication interfere with or affect the results of certain lab tests?

A: Official warnings indicate that the medication may interfere with the results of certain laboratory tests. Specifically, promethazine may cause false-positive or false-negative results in certain immunological urine pregnancy tests, and it may also cause a false positive result for amphetamines in some urine drug screenings.

Q: Is there a known risk of low blood cell counts associated with this medicine?

A: Yes, Bone-Marrow Depression is a serious risk noted in the official safety information. Rare reports of Leukopenia (low white blood cells) and agranulocytosis have been documented, especially when the promethazine component is used alongside other agents that may also affect bone marrow.

How to Store and Dispose of Promethazine With Codeine

Promethazine with Codeine Oral Solution must be stored in alignment with official regulatory requirements to maintain stability and prevent misuse.

Mandatory Storage Conditions

The medicine must be stored at Controlled Room Temperature, which is maintained between 20 C to 25 C (68 F to 77 F). The solution must be protected from light and the bottle must be kept tightly closed when not in use. It is strictly required to not freeze the medication.

Security and Disposal

Given the presence of codeine, the product must be stored in a safe, secure place and out of the reach of children. Unused or expired medication should be disposed of using an official drug take-back program. If a program is unavailable, follow specific household disposal guidelines for controlled substances; do not flush the solution down the toilet or pour it down a sink.